Get the Stockscreener App
29.24
3.28%
-0.9596
Apellis Pharmaceuticals Inc stock is traded at $29.24, with a volume of 291.84K.
It is down -3.28% in the last 24 hours and down -15.65% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$30.20
Open:
$30
24h Volume:
291.84K
Relative Volume:
0.11
Market Cap:
$3.76B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-14.40
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+0.69%
1M Performance:
-15.65%
6M Performance:
-13.04%
1Y Performance:
-56.21%
1-Day Range:
$29.20
$30.26
1-Week Range:
$27.91
$30.60
52-Week Range:
$24.34
$71.90
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
29.27 | 3.76B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.99 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.58 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.42 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.27 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Fierce Biotech Layoff Tracker 2025: Viracta shuts down; Layoffs hit Frontier - Fierce Biotech
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, - GlobeNewswire
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and MaplebearJohnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire
Geographic Atrophy Market Poised for Massive Growth - openPR
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside Apellis' Strategic Move: New Talent Secured with 7,805 RSU Compensation Package - StockTitan
(APLS) Technical Data - Stock Traders Daily
KBC Group NV Has $3.33 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Cedric Francois Sells 2,824 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Sippican Capital Advisors Sells 9,560 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Morgan Stanley's Strategic Acquisition of Apellis Pharmaceuticals Shares - GuruFocus.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan Sells 546 Shares - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $24,354.00 in Stock - MarketBeat
Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Decreases By 16.0% - MarketBeat
Apellis Pharmaceuticals' (APLS) Sector Perform Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $20,516.40 in Stock - MarketBeat
Apellis Pharmaceuticals chief development officer sells $8,207 in stock - MSN
Apellis Pharmaceuticals chief scientific officer sells $24,386 in stock - MSN
Apellis Pharmaceuticals officer sells shares for $10,776 - MSN
Apellis Pharmaceuticals chief development officer sells $8,207 in stock By Investing.com - Investing.com Canada
Layoff Tracker: Rentschler’s Cell and Gene Therapy Exit Could Affect Up to 30 - BioSpace
Apellis Pharmaceuticals chief scientific officer sells $24,386 in stock By Investing.com - Investing.com Australia
Apellis Pharmaceuticals general counsel sells $20,518 in stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals CFO sells $16,119 in stock - MSN
Apellis Pharmaceuticals officer sells shares for $10,776 By Investing.com - Investing.com Australia
Apellis Pharmaceuticals CFO sells $16,119 in stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals general counsel sells $20,518 in stock - Investing.com
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apellis Pharmaceuticals Inc Stock (APLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Townsend Adam J. | Chief Commercial Officer |
Jan 29 '25 |
Sale |
29.52 |
695 |
20,519 |
84,050 |
| Sullivan Timothy Eugene | Chief Financial Officer |
Jan 29 '25 |
Sale |
29.52 |
546 |
16,120 |
128,665 |
| Nicholson Nur | Chief Technical Officer |
Jan 29 '25 |
Sale |
29.52 |
825 |
24,357 |
83,664 |
| Lewis Karen | Chief People Officer |
Jan 29 '25 |
Sale |
29.52 |
364 |
10,747 |
70,251 |
| Eisele Jeffrey | Chief Development Officer |
Jan 29 '25 |
Sale |
29.52 |
278 |
8,208 |
55,312 |
| Deschatelets Pascal | Chief Scientific Officer |
Jan 29 '25 |
Sale |
29.52 |
826 |
24,386 |
1,147,716 |
| Francois Cedric | Chief Executive Officer |
Jan 29 '25 |
Sale |
29.52 |
2,824 |
83,375 |
415,695 |
| DeLong Mark Jeffrey | Chief Business & Strat Officer |
Jan 29 '25 |
Sale |
29.52 |
365 |
10,776 |
84,308 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):